Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rating on Regeneron Pharmaceuticals, Inc.






